142 related articles for article (PubMed ID: 26954925)
1. [Introduction of biosimilars requires careful monitoring].
Marsal J; Hertervig E
Lakartidningen; 2016 Mar; 113():. PubMed ID: 26954925
[No Abstract] [Full Text] [Related]
2. Biosimilar competition: lessons from Europe.
Grabowski H; Guha R; Salgado M
Nat Rev Drug Discov; 2014 Feb; 13(2):99-100. PubMed ID: 24445562
[No Abstract] [Full Text] [Related]
3. Biosimilars: where we were and where we are.
Challand R; Gorham H; Constant J
J Biopharm Stat; 2014; 24(6):1154-64. PubMed ID: 25036475
[TBL] [Abstract][Full Text] [Related]
4. [Cheaper with biosimilars, but safety comes first].
Mellstedt H
Lakartidningen; 2014 May 27-Jun 10; 111(22-23):1011. PubMed ID: 24946487
[No Abstract] [Full Text] [Related]
5. [Patient safety first. position paper of the German Rheumatism -- Ligazur introduction of biosimilars].
Z Rheumatol; 2014 Sep; 73(7):676. PubMed ID: 25320752
[No Abstract] [Full Text] [Related]
6. [Biosimilars].
Krämer I
Ther Umsch; 2011 Nov; 68(11):659-66. PubMed ID: 22045529
[TBL] [Abstract][Full Text] [Related]
7. Competition in the Age of Biosimilars.
Chandra A; Vanderpuye-Orgle J
JAMA; 2015 Jul; 314(3):225-6. PubMed ID: 26197179
[No Abstract] [Full Text] [Related]
8. [Biosimilars - Potential, risks and open questions].
Dtsch Med Wochenschr; 2014 Jan; 139(1-2):12-3. PubMed ID: 24551883
[No Abstract] [Full Text] [Related]
9. Global regulatory standards for the approval of biosimilars.
Mounho B; Phillips A; Holcombe K; Grampp G; Lubiniecki T; Mollerup I; Jones C
Food Drug Law J; 2010; 65(4):819-37, ii-iii. PubMed ID: 24479248
[TBL] [Abstract][Full Text] [Related]
10. Biosimilar safety factors in clinical practice.
Reinisch W; Smolen J
Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S9-15. PubMed ID: 26058551
[TBL] [Abstract][Full Text] [Related]
11. Biosimilars: Considerations for Oncology Nurses
.
Vizgirda V; Jacobs I
Clin J Oncol Nurs; 2017 Apr; 21(2):E54-E60. PubMed ID: 28315542
[TBL] [Abstract][Full Text] [Related]
12. Current Japanese Regulatory Systems for Generics and Biosimilars.
Kuribayashi R; Sawanobori K
J Pharm Sci; 2018 Mar; 107(3):785-787. PubMed ID: 29113922
[TBL] [Abstract][Full Text] [Related]
13. The Biosimilar Pipeline Seams Seem To Be Bursting.
Reinke T
Manag Care; 2017 Mar; 26(3):24-25. PubMed ID: 28510516
[TBL] [Abstract][Full Text] [Related]
14. What are biosimilars and are they important?
Drug Ther Bull; 2013 May; 51(5):57-60. PubMed ID: 23657197
[TBL] [Abstract][Full Text] [Related]
15. Biosimilar regulation in the EU.
Kurki P; Ekman N
Expert Rev Clin Pharmacol; 2015; 8(5):649-59. PubMed ID: 26294076
[TBL] [Abstract][Full Text] [Related]
16. Biosimilars: the paradox of sharing the same pharmacological action without full chemical identity.
Pani L; Montilla S; Pimpinella G; Bertini Malgarini R
Expert Opin Biol Ther; 2013 Oct; 13(10):1343-6. PubMed ID: 23805906
[TBL] [Abstract][Full Text] [Related]
17. Japanese regulatory authority's perspective on biosimilars.
Nagai S; Yanagihara R; Kishioka Y
Lancet Oncol; 2015 Mar; 16(3):e101. PubMed ID: 25752552
[No Abstract] [Full Text] [Related]
18. The Diversity of Biosimilar Design and Development: Implications for Policies and Stakeholders.
Grampp G; Ramanan S
BioDrugs; 2015 Dec; 29(6):365-72. PubMed ID: 26581551
[TBL] [Abstract][Full Text] [Related]
19. Biosimilars: The US Regulatory Framework.
Christl LA; Woodcock J; Kozlowski S
Annu Rev Med; 2017 Jan; 68():243-254. PubMed ID: 27813877
[TBL] [Abstract][Full Text] [Related]
20. Factors influencing the economics of biosimilars in the US.
Mehr SR; Brook RA
J Med Econ; 2017 Dec; 20(12):1268-1271. PubMed ID: 28796564
[No Abstract] [Full Text] [Related]
[Next] [New Search]
